Community Advisory Board

CMLCAB Logo 

What is the CML Community Advisory Board (CML-CAB)

CML Community Advisory Board (CML-CAB) is a working group of the CML Advocates Network. It is a global panel of 18 leading patient advocates from all world regions (“CML-CAB members”) who all speak from the unique perspective of a CML patient or relative. CML-CAB members work together to address issues of strategic importance to the community and advocate for the best possible research and equal access to the most innovative treatment & care for CML patients around the world. CML-CAB monitors pharmaceutical developments and research in CML through active and targeted interaction, long-term cooperation and continued dialogue with pharmaceutical partners, regulators, medical experts, and the scientific CML-community.

Watch our video to learn more about CML-CABs!

 

 

CML-CAB Objectives & Strategy

Find out more about CML-CAB objectives and strategic priorities.

 

From History to Present 

Find out more about CML-CAB history and current activities.

 

How does CML-CAB work?

Find out more about CML-CAB work and development.

 

Composition of CML-CAB

Find out more about CML-CAB team

 

Participation in CML-CAB meetings

Find out more about CML-CAB members' participation.

 

Interested?

If you are a private individual and CML patient expert interested in becoming a CML-CAB member OR if you are a representative of a pharmaceutical company committed to improving the lives of CML patients around the world and interested in being invited to a CML-CAB or engaging in a working group, please contact our CML-CAB Officer Nicole at nicole@cmladvocates.net

 

Other ways of engagement

The CML Advocates Network engages in multiple ways with partners in the life-sciences industry. Some of these engagements are formally operated under CML-CAB, the most meaningful and impactful being the CML Working Groups, delegated by CML-CAB to take on ongoing tasks which require frequent follow-up.

Here you will find a list of current working groups operated under CML-CAB.

 

Upcoming CML-CABs

CML-CAB with Novartis on “Future treatments and current access”
Date: 18 February, 2021
Details will follow as they become available.

 

 

EU e-Privacy Directive